COVID-19 and coagulation dysfunction in adults: A systematic review and meta-analysis.


Journal

Journal of medical virology
ISSN: 1096-9071
Titre abrégé: J Med Virol
Pays: United States
ID NLM: 7705876

Informations de publication

Date de publication:
02 2021
Historique:
received: 04 06 2020
revised: 15 07 2020
accepted: 18 07 2020
pubmed: 25 7 2020
medline: 15 1 2021
entrez: 25 7 2020
Statut: ppublish

Résumé

The outbreak of 2019 novel coronavirus disease (COVID-19) has posed a grave threat to the global public health. The COVID-19-induced infection is closely related to coagulation dysfunction in the affected patients. This paper attempts to conduct a meta-analysis and systematically review the blood coagulation indicators in patients with severe COVID-19. A meta-analysis of eligible studies was performed to compare the blood coagulation indicators in patients with severe and nonsevere COVID-19. PubMed, Embase, Web of Science, and the Cochrane Library were searched for studies published between 1 December 2019 and 7 May 2020. A total of 13 studies with 1341 adult patients were enrolled in this analysis. Platelet (weighted mean difference [WMD] = -24.83, 95% confidence interval [CI]: -34.12 to -15.54; P < .001), d-dimer (WMD = 0.19, 95% CI: 0.09-0.29; P < .001), and fibrinogen (WMD = 1.02, 95% CI: 0.50-1.54; P < .001) were significantly associated with the severity in patients with COVID-19. The meta-analysis revealed that no correlation was evident between an increased severity risk of COVID-19 and activated partial thromboplastin time (WMD = -1.56, 95% CI: -5.77 to 2.64; P = .468) or prothrombin time (WMD = 0.19, 95% CI: -0.13 to 0.51; P = .243). The single arm meta-analysis showed that compared with the nonsevere group, the severe group had a lower pooled platelet (165.12 [95% CI: 157.38-172.85] vs 190.09 [95% CI: 179.45-200.74]), higher d-dimer (0.49 [95% CI: 0.33-0.64] vs 0.27 [95% CI: 0.20-0.34]), and higher fibrinogen (4.34 [95% CI: 1.98-6.70] vs 3.19 [95% CI: 1.13-5.24]). Coagulation dysfunction is closely related to the severity of patients with COVID-19, in which low platelet, high d-dimer, and fibrinogen upon admission may serve as risk indicators for increased aggression of the disease. These findings are of great clinical value for timely and effective treatment of the COVID-19 cases.

Identifiants

pubmed: 32706426
doi: 10.1002/jmv.26346
pmc: PMC7405098
doi:

Substances chimiques

Fibrin Fibrinogen Degradation Products 0
fibrin fragment D 0
Fibrinogen 9001-32-5

Types de publication

Journal Article Meta-Analysis Systematic Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

934-944

Informations de copyright

© 2020 The Authors. Journal of Medical Virology published by Wiley Periodicals LLC.

Références

Eur J Epidemiol. 2010 Sep;25(9):603-5
pubmed: 20652370
J Med Virol. 2020 Jul;92(7):791-796
pubmed: 32181911
Br J Haematol. 2020 Jun;189(6):1050-1052
pubmed: 32304581
Semin Thromb Hemost. 2013 Jul;39(5):559-66
pubmed: 23625756
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Respir Med Case Rep. 2019 Jun 14;28:100884
pubmed: 31245274
J Med Virol. 2020 Jul;92(7):797-806
pubmed: 32198776
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
BMJ. 2003 Jun 21;326(7403):1358-62
pubmed: 12816821
J Med Virol. 2021 Feb;93(2):934-944
pubmed: 32706426
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Br J Haematol. 2020 Jun;189(6):1044-1049
pubmed: 32330308
Thromb Haemost. 2020 Jun;120(6):998-1000
pubmed: 32316063
Thromb Res. 2019 Sep;181:17-23
pubmed: 31325905
Infection. 2020 Aug;48(4):543-551
pubmed: 32342479
N Engl J Med. 2020 May 7;382(19):1861-1862
pubmed: 32220206
Semin Hematol. 1988 Apr;25(2):84-90
pubmed: 2455348
Clin Chim Acta. 2020 Jul;506:145-148
pubmed: 32178975
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Front Immunol. 2014 Dec 18;5:649
pubmed: 25566260
J Thromb Haemost. 2020 Jun;18(6):1324-1329
pubmed: 32306492
Hepatology. 1992 Oct;16(4):920-3
pubmed: 1328011
J Thromb Haemost. 2020 Apr;18(4):844-847
pubmed: 32073213
J Thromb Haemost. 2020 Jun;18(6):1469-1472
pubmed: 32302435
J Extracell Vesicles. 2019 Mar 05;8(1):1585163
pubmed: 30863515
BMC Med Res Methodol. 2005 Apr 20;5:13
pubmed: 15840177
Hepatol Res. 2020 Aug;50(8):924-935
pubmed: 32386449
J Thromb Thrombolysis. 2020 Aug;50(2):281-286
pubmed: 32394236
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67
pubmed: 31573350
Eur Rev Med Pharmacol Sci. 2020 Mar;24(6):3404-3410
pubmed: 32271459
QJM. 2003 Oct;96(10):711-29
pubmed: 14500858
Hematology. 2005 Apr;10(2):101-5
pubmed: 16019455
Clin Chem. 2016 May;62(5):699-707
pubmed: 26955824
Blood. 2016 Jun 16;127(24):3062-72
pubmed: 26956172
Thromb Res. 2020 Aug;192:3-8
pubmed: 32407937
Ann Intern Med. 2020 Aug 18;173(4):268-277
pubmed: 32374815
Radiology. 2020 Sep;296(3):E189-E191
pubmed: 32324102
Br J Haematol. 2001 Oct;115(1):3-12
pubmed: 11722403
Clin Chem Lab Med. 2020 Jun 25;58(7):1106-1115
pubmed: 32352397
J Med Virol. 2012 Oct;84(10):1680-96
pubmed: 22930518
J Thromb Haemost. 2020 Aug;18(8):1995-2002
pubmed: 32369666
J Clin Virol. 2020 Jun;127:104361
pubmed: 32344320
J Intern Med. 2015 May;277(5):573-84
pubmed: 25161014
JCI Insight. 2020 Jun 4;5(11):
pubmed: 32329756
Mayo Clin Proc. 2007 Jul;82(7):864-73
pubmed: 17605969
J Med Virol. 2020 Sep;92(9):1533-1541
pubmed: 32181903
EBioMedicine. 2020 May;55:102763
pubmed: 32361250
Allergy. 2020 Jul;75(7):1730-1741
pubmed: 32077115
Circulation. 2020 Jun 2;141(22):1739-1741
pubmed: 32271624
Liver Int. 2020 Jun;40(6):1321-1326
pubmed: 32239591
J Thromb Haemost. 2020 Jul;18(7):1738-1742
pubmed: 32302438
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Int J Infect Dis. 2020 Jun;95:332-339
pubmed: 32334118
Ann Transl Med. 2020 Feb;8(3):48
pubmed: 32154288

Auteurs

Jing Lin (J)

Department of Critical Care Medicine, Fujian Provincial Hospital, Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China.

Han Yan (H)

Department of Cardiology, Fujian Provincial Hospital, Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China.

Hanchuan Chen (H)

Department of Cardiology, Fujian Provincial Hospital, Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China.

Chen He (C)

Department of Cardiology, Fujian Provincial Hospital, Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China.

Chunjin Lin (C)

Department of Cardiology, Fujian Provincial Hospital, Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China.

Haoming He (H)

Department of Cardiology, Fujian Provincial Hospital, Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China.

Sicheng Zhang (S)

Department of Cardiology, Fujian Provincial Hospital, Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China.

Songjing Shi (S)

Department of Critical Care Medicine, Fujian Provincial Hospital, Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China.

Kaiyang Lin (K)

Department of Cardiology, Fujian Provincial Hospital, Shengli Clinical Medical College, Fujian Medical University, Fuzhou, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH